Andrew Ko, MD

Professor

Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
06/2001 - Medical oncology (fellowship), Stanford University
06/1998 - Internal Medicine (internship and residency), Beth Israel/Harvard Medical School
M.D., 05/1995 - Medicine, Johns Hopkins School of Medicine
Sc.B., 05/1991 - Applied Mathematics and Biology, Brown University
Publications

  1. Sarwahi V, Rahman E, Eigo K, Galina J, Hasan S, Ko A, Lo Y, Amaral T, Djukic A, Santiago M, Schneider J. Perioperative Considerations in Patients with Rett Syndrome as Compared to Those with Cerebral Palsy. Spine 2024. PMID: 39505565


  2. Ko A, Vo AM, Miller N, Liang A, Baumbach M, Riley Argue J, Manche N, Gonzalez L, Austin N, Carver P, Procell J, Elzein H, Pan M, Zeidan N, Kasper W, Speer S, Liang Y, Pettus BJ. The Use of Breast-specific Gamma Imaging as a Low-Cost Problem-Solving Strategy for Avoiding Biopsies in Patients With Inconclusive Imaging Findings on Mammography and Ultrasonography. Journal of breast imaging 2024. PMID: 39162574


  3. Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Annals of surgical oncology 2024. PMID: 39068310


  4. Till JE, McDaniel L, Chang C, Long Q, Pfeiffer SM, Lyman JP, Padrón LJ, Maurer DM, Yu JX, Spencer CN, Gherardini PF, Da Silva DM, LaVallee TM, Abbott C, Chen RO, Boyle SM, Bhagwat N, Cannas S, Sagreiya H, Li W, Yee SS, Abdalla A, Wang Z, Yin M, Ballinger D, Wissel P, Eads J, Karasic T, Schneider C, O'Dwyer P, Teitelbaum U, Reiss KA, Rahma OE, Fisher GA, Ko AH, Wainberg ZA, Wolff RA, O'Reilly EM, O'Hara MH, Cabanski CR, Vonderheide RH, Carpenter EL. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nature communications 2024. PMID: 38982051


  5. Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Annals of surgical oncology 2024. PMID: 38879670


  6. Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO precision oncology 2024. PMID: 38865673


  7. Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, Ko A, Adelson PD, Lega B, Konrad P, Calle G, Vale FL, Bucholz R, Richardson RM. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectronic medicine 2024. PMID: 38475923


  8. Ko AH, Coveler AL, Schlechter BL, Bekaii-Saab T, Wolpin BM, Clark JW, Bockorny B, Bai LY, Lin YC, Chiang E, Langecker P, Lin SY. A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer. Investigational new drugs 2024. PMID: 38441850


  9. Soto M, Filbert EL, Yang H, Starzinski S, Starzinski A, Gin M, Chen BK, Le P, Li T, Bol B, Cheung A, Zhang L, Hsu FJ, Ko AH, Fong L, Keenan BP. Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer. Cancer research communications 2024. PMID: 38181044


  10. O'Reilly EM, Ko AH, Friedberg JW. Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023. PMID: 38100990


  11. Gordon JW, Chen HY, Nickles T, Lee PM, Bok R, Ohliger MA, Okamoto K, Ko AH, Larson PEZ, Wang ZJ. Hyperpolarized 13 C Metabolic MRI of Patients with Pancreatic Ductal Adenocarcinoma. Journal of magnetic resonance imaging : JMRI 2023. PMID: 38041836


  12. Ko AH. Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023. PMID: 37847994


  13. Johansen N, Somasundaram S, Travaglini KJ, Yanny AM, Shumyatcher M, Casper T, Cobbs C, Dee N, Ellenbogen R, Ferreira M, Goldy J, Guzman J, Gwinn R, Hirschstein D, Jorstad NL, Keene CD, Ko A, Levi BP, Ojemann JG, Pham T, Shapovalova N, Silbergeld D, Sulc J, Torkelson A, Tung H, Smith K, Lein ES, Bakken TE, Hodge RD, Miller JA. Interindividual variation in human cortical cell type abundance and expression. Science (New York, N.Y.) 2023. PMID: 37824649


  15. Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37433437


  16. Ko AH. Flashback Foreword: KRAS Is a Selection Marker for Panitumumab Benefit in Patients With Metastatic Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023. PMID: 37315388


  17. Youngerman BE, Banu MA, Khan F, McKhann GM, Schevon CA, Jagid JR, Cajigas I, Theodotou CB, Ko A, Buckley R, Ojemann JG, Miller JW, Laxton AW, Couture DE, Popli GS, Buch VP, Halpern CH, Le S, Sharan AD, Sperling MR, Mehta AD, Englot DJ, Neimat JS, Konrad PE, Sheth SA, Neal EG, Vale FL, Holloway KL, Air EL, Schwalb JM, D'Haese PF, Wu C. Long-term outcomes of mesial temporal laser interstitial thermal therapy for drug-resistant epilepsy and subsequent surgery for seizure recurrence: a multi-centre cohort study. Journal of neurology, neurosurgery, and psychiatry 2023. PMID: 37336643


  18. Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The oncologist 2023. PMID: 36940261


  19. Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M, APACT Investigators. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. PMID: 36521097


  20. O'Reilly EM, Ko AH. Precision Medicine and Immunotherapy in GI Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. PMID: 35839433


  21. Munigala S, Gardner TB, O'Reilly EM, Fern?ndez-Del Castillo C, Ko AH, Pleskow D, Vollmer CM, Searle NA, Bakelman D, Holt JM, Gelrud A. Helping Patients Understand Pancreatic Cancer Using Animated Pancreas Patient Education With Visual Formats of Learning. Pancreas 2022. PMID: 36206469


  22. Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2022. PMID: 35662283


  23. Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Pancreas 2022. PMID: 35695740


  24. Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34864778


  25. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. The oncologist 2021. PMID: 34506673


  26. Tsang ES, Walker EJ, Carnevale J, Fisher GA, Ko AH. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair deficient pancreatic cancer. Immunotherapy 2021. PMID: 34338034


  27. Wong A, Zhu D, Tong JY, Ko A, Tham T, Kraus D. The jaw-dropping costs of oral cavity cancer malpractice. Head & neck 2021. PMID: 34050580


  28. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. The New England journal of medicine 2021. PMID: 33789008


  29. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2021. PMID: 33845462


  30. O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet. Oncology 2021. PMID: 33387490


  31. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA oncology 2020. PMID: 32880601


  32. Hoang T, Dayyani F, Alfaro A, Huynh J, Ji J, Ko AH, Cho M, Hiyama D. Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. Journal of gastrointestinal oncology 2020. PMID: 33209490


  33. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular therapy : the journal of the American Society of Gene Therapy 2020. PMID: 32730744


  34. Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel FE, Bagaev AV, Elemento O, Betel D, Giannakakou P, Lenz HJ. Multicenter phase II study of Cabazitaxel in advanced gastroesophageal cancer: Association of HER2 Expression and M2-like Tumor Associated Macrophages with Patient Outcome. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32641434


  35. Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR. American journal of roentgenology 2020. PMID: 32755156


  37. Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners BL, Ferguson A, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32591464


  38. Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume Annals of oncology : official journal of the European Society for Medical Oncology 2020. PMID: 32507672


  39. Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients. The oncologist 2020. PMID: 32390297


  40. Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, Coussens LM, Jaffee EM, Le DT. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020. PMID: 32273276


  41. Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. The oncologist 2020. PMID: 32031306


  42. Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Annals of oncology : official journal of the European Society for Medical Oncology 2020. PMID: 31912800


  43. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. American journal of clinical oncology 2019. PMID: 31634155


  44. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. Journal of gastrointestinal cancer 2018. PMID: 30058032


  45. Ko AH, Nakakura EK. Adjuvant Therapy for Ampullary Cancer. JAMA surgery 2019. PMID: 31141140


  46. Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas 2019. PMID: 31268983


  47. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. Journal of the National Cancer Institute 2019. PMID: 31086963


  48. Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clinical cancer research : an official journal of the American Association for Cancer Research 2019. PMID: 31126960


  49. Wu C, Jermakowicz WJ, Chakravorti S, Cajigas I, Sharan AD, Jagid JR, Matias CM, Sperling MR, Buckley R, Ko A, Ojemann JG, Miller JW, Youngerman B, Sheth SA, McKhann GM, Laxton AW, Couture DE, Popli GS, Smith A, Mehta AD, Ho AL, Halpern CH, Englot DJ, Neimat JS, Konrad PE, Neal E, Vale FL, Holloway KL, Air EL, Schwalb J, Dawant BM, D'Haese PF. Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients. Epilepsia 2019. PMID: 31112302


  50. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Familial cancer 2018. PMID: 30267352


  51. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? The American journal of surgical pathology 2018. PMID: 30211728


  52. Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic Adenocarcinoma, Version 1.2019. Journal of the National Comprehensive Cancer Network : JNCCN 2019. PMID: 30865919


  53. Munigala S, Gardner TB, O'Reilly EM, Castillo CF, Ko AH, Pleskow D, Mills JB, Vollmer CM, Searle NA, Alsante M, Holt JM, Gelrud A. Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning. Pancreas 2018. PMID: 30286013


  54. Ko AH. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary surgery and nutrition 2018. PMID: 30498720


  55. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR. American journal of roentgenology 2018. PMID: 30063366


  56. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA oncology 2018. PMID: 29543932


  57. Ko AH. Shifting the treatment model for resectable pancreatic cancer. The lancet. Gastroenterology & hepatology 2018. PMID: 29625842


  58. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018. PMID: 29380678


  59. Ko AH. Clinical Management: Metastatic Disease. Cancer journal (Sudbury, Mass.) 2017. PMID: 29189332


  60. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. The oncologist 2017. PMID: 28935773


  61. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2017. PMID: 28784865


  63. Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. The oncologist 2017. PMID: 28592615


  66. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. Journal of gastrointestinal oncology 2016. PMID: 28078110


  67. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. American journal of clinical oncology 2016. PMID: 25068471


  68. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas 2016. PMID: 27171514


  69. Ko AH. Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer. Journal of oncology practice 2016. PMID: 27621334


  70. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. Journal of surgical oncology 2016. PMID: 27569043


  71. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Journal of surgical oncology 2016. PMID: 27444658


  72. Williams JR, Tenforde MW, Chan JD, Ko A, Graham SM. Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection. Medical mycology case reports 2016. PMID: 27656356


  73. Wang VE, Grandis JR, Ko AH. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clinical cancer research : an official journal of the American Association for Cancer Research 2016. PMID: 27370606


  74. Ko AH. Raising the bar for the adjuvant treatment of pancreatic cancer. Lancet (London, England) 2016. PMID: 27265348


  75. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016. PMID: 27247216


  77. Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Investigational new drugs 2016. PMID: 26994014


  78. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas 2016. PMID: 26390428


  80. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast cancer research and treatment 2016. PMID: 26875185


  81. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2016. PMID: 26802160


  82. Carnevale J, Ko AH. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future oncology (London, England) 2015. PMID: 26685802


  83. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015. PMID: 26251290


  84. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer discovery 2015. PMID: 26109333


  85. Pollom EL, Koong AC, Ko AH. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematology/oncology clinics of North America 2015. PMID: 26226908


  86. Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015. PMID: 25918299


  87. Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer 2015. PMID: 25649483


  88. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2015. PMID: 25993177


  90. Walker EJ, Ko AH, Holly EA, Bracci PM. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. International journal of cancer 2014. PMID: 25091126


  91. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 25099441


  93. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. Journal of gastrointestinal cancer 2014. PMID: 24448917


  94. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 2014. PMID: 24622062


  95. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 2014. PMID: 24633933


  96. Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World journal of gastroenterology 2014. PMID: 24605022


  97. Cinar P, Ko AH. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2014. PMID: 24586078


  98. Ko AH. Expanding options for pancreatic cancer... so where do we go from here? Oncology (Williston Park, N.Y.) 2014. PMID: 24683713


  99. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British journal of cancer 2013. PMID: 24022191


  100. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Molecular cancer therapeutics 2013. PMID: 23918833


  101. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British journal of cancer 2013. PMID: 23880820


  102. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Annals of oncology : official journal of the European Society for Medical Oncology 2013. PMID: 23519998


  103. Lee MS, Seo J, Choi DY, Lee EW, Ko A, Ha NC, Yoon JB, Lee HW, Kim KP, Song J. Stabilization of p21 (Cip1/WAF1) following Tip60-dependent acetylation is required for p21-mediated DNA damage response. Cell death and differentiation 2012. PMID: 23238566


  104. Ko A, Su DK, Born D, DeSantis A, Alan Failor R, Ferreira M. Two patients with primary sellar leiomyomas, a rare entity. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2012. PMID: 23219820


  105. Ko AH, Cella D. Achieving the best of both worlds. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012. PMID: 23213099


  106. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. American journal of clinical oncology 2012. PMID: 21552099


  107. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer chemotherapy and pharmacology 2012. PMID: 23053263


  108. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012. PMID: 22679115


  109. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Physical biology 2012. PMID: 22306705


  110. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Physical biology 2012. PMID: 22306768


  111. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011. PMID: 22147736


  112. Ko AH. FOLFIRINOX: a small step or a great leap forward? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011. PMID: 21900100


  113. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Investigational new drugs 2011. PMID: 21629990


  114. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature medicine 2011. PMID: 21460848


  115. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegård D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis and cartilage 2011. PMID: 21396468


  116. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011. PMID: 21245436


  117. Ko AH, Crane CH. Radiation therapy in operable and locally advanced pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2010. PMID: 20876542


  118. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer chemotherapy and pharmacology 2010. PMID: 20130876


  119. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research 2009. PMID: 19706807


  120. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology 2008. PMID: 19041649


  122. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Investigational new drugs 2008. PMID: 18379729


  123. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics : targets & therapy 2008. PMID: 19707431


  124. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer investigation 2008. PMID: 18181045


  125. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. Journal of immunotherapy (Hagerstown, Md. : 1997) 2007. PMID: 17893568


  127. Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis and cartilage 2007. PMID: 17631392


  129. Lam K, Lam FK, Lau KK, Chan YK, Kan EY, Woo J, Wong FK, Ko A. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society 2007. PMID: 17266075


  130. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics 2007. PMID: 17363191


  131. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005. PMID: 16344320


  132. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Seminars in radiation oncology 2005. PMID: 16183478


  133. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2005. PMID: 16194454


  134. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer 2005. PMID: 15999098


  135. Ko AH, Bergsland EK, Lee GA. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Digestive diseases and sciences 2003. PMID: 12645810


  136. Ko AH, Yuen AR. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leukemia & lymphoma 2002. PMID: 12685833


  137. Ko AH, Tempero MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Current oncology reports 2002. PMID: 11937010


  138. Harmon EB, Ko AH, Kim SK. Hedgehog signaling in gastrointestinal development and disease. Current molecular medicine 2002. PMID: 11898849


  139. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP. AR and ER interaction with a p21-activated kinase (PAK6). Molecular endocrinology (Baltimore, Md.) 2002. PMID: 11773441


  140. Patterson S, Ko A, O'Connell TX. Radiation after mastectomy in high-risk patients: is it necessary? The American surgeon 2001. PMID: 11768832


  141. Garcia-Oria M, Ali A, Reynolds JD, Clary E, Gandsas A, Cummings T, McMahon RL, Bruch S, Fina M, Ko A, Eubanks S. Histologic evaluation of fetal brains following maternal pneumoperitoneum. Surgical endoscopy 2001. PMID: 11727136


  142. Nugent CT, Morgan DJ, Biggs JA, Ko A, Pilip IM, Pamer EG, Sherman LA. Characterization of CD8+ T lymphocytes that persist after peripheral tolerance to a self antigen expressed in the pancreas. Journal of immunology (Baltimore, Md. : 1950) 2000. PMID: 10605011


  143. Chen Z, Ko A, Yang J, Jordan VC. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. British journal of cancer 1998. PMID: 9460986


  144. Jin H, Yang R, Keller GA, Ryan A, Ko A, Finkle D, Swanson TA, Li W, Pennica D, Wood WI, Paoni NF. In vivo effects of cardiotrophin-1. Cytokine 1996. PMID: 9050750


  145. Lai J, Jin H, Yang R, Winer J, Li W, Yen R, King KL, Zeigler F, Ko A, Cheng J, Bunting S, Paoni NF. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. The American journal of physiology 1996. PMID: 8997275


  146. Gallant JE, Ko AH. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996. PMID: 8729207


  148. Ko AH. Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China. The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha 1994. PMID: 8022868